NCT06696183
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT06696183
Title Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive Treatment (SEQUENCE)
Acronym SEQUENCE
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements Yes
Sponsors Technische Universität Dresden
Indications
Therapies
Age Groups: adult | senior
Covered Countries DEU